<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653835</url>
  </required_header>
  <id_info>
    <org_study_id>P03435</org_study_id>
    <nct_id>NCT00653835</nct_id>
  </id_info>
  <brief_title>Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)</brief_title>
  <official_title>SCH 58235: A Multicenter, Randomised, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, and Tolerability Of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg vs Ezetimibe Placebo With Simvastatin 20 mg in Untreated Subjects With Primary Hypercholesterolaemia And Coronary Heart Disease (Protocol P03435)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will assess whether co-administration of ezetimibe 10 mg with simvastatin 20 mg
      will be more effective than treatment with simvastatin 20 mg alone in reducing LDL-C
      concentrations when administered for 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2003</start_date>
  <completion_date type="Actual">August 1, 2004</completion_date>
  <primary_completion_date type="Actual">August 1, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in LDL-C from baseline to endpoint.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who achieve LDL-C ESC goal (ie, &lt;3 mmol/L [115 mg/dL]) at endpoint.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to endpoint in total cholesterol, HDL-C and triglycerides.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events, laboratory test results, vital signs.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Simvastatin</intervention_name>
    <description>oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks</description>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <other_name>SCH 58235</other_name>
    <other_name>Zetia</other_name>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;=18 years and &lt;= 75 years of age

          -  LDL-C concentration &gt;= 3.3 mmol/L (130 mg/dL) to &lt;= 4.9 mmol/L (190 mg/dL) at
             baseline.

          -  Triglyceride concentration &lt;3.99 mmol/L (350 mg/dL) at baseline.

          -  Documented coronary heart disease (CHD), which will include one or more of the
             following features: documented stable angina (with evidence of ischemia on exercise
             testing); history of MI; history of PCI (primarily PTCA with or without stent
             replacement); symptomatic peripheral vascular disease; documented history of
             atherothrombotic cerebrovascular disease; and/or documented history of non-Q wave MI.

          -  Stable weight history for at least 4 weeks prior to entry into study at baseline.

          -  Female subjects of childbearing potential must be using an acceptable method of birth
             control or be surgically sterilized.

        Exclusion Criteria:

          -  Body mass index (BMI) &gt;=35 kg/m^2 at baseline.

          -  Subjects whose liver transaminases (ALT, AST) are &gt;1.5 times the upper limit of normal
             and with active liver diseases at baseline.

          -  Subjects with evidence of current myopathy (including subjects with CK&gt;1.5 times above
             the upper limit of normal) at baseline.

          -  Subjects with clinical laboratory tests (CBC, blood chemistries, urinalysis) outside
             the normal range that are clinically acceptable to the investigator at baseline.

          -  Subjects with Type II diabetes mellitus who are poorly controlled (HbA1c&gt;9%) or newly
             diagnosed (within 3 months) or who have had a change in anti-diabetic therapy within 3
             months of baseline.

          -  Subjects with Type I diabetes mellitus who have not been on a stable insulin regimen
             for 3 months prior to baseline, or who have a recent history of repeated hypoglycaemia
             or unstable glycaemic control.

          -  Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.

          -  Female subjects who consume &gt;14 units and male subjects who consume &gt;21 units of
             alcohol per week.

          -  Female subjects who are pregnant or breast feeding.

          -  Subjects who have not observed the designated washout periods for any of the
             prohibited medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract. 2006 Aug;60(8):914-21.</citation>
    <PMID>16893434</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

